Alibaba
BABA
Apple
AAPL
Netflix
NFLX
Tesla
TSLA
Microsoft
MSFT
US Stock MarketDetailed Quotes
CPIX Cumberland Pharmaceuticals
- 4.130
- -0.200-4.62%
Close Mar 27 16:00 ET
- 4.130
- 0.0000.00%
Post 20:01 ET
57.69MMarket Cap-8.98P/E (TTM)
4.300High3.910Low85.04KVolume4.300Open4.330Pre Close349.07KTurnover1.30%Turnover RatioLossP/E (Static)13.97MShares7.25052wk High2.52P/B26.98MFloat Cap1.04052wk Low--Dividend TTM6.53MShs Float17.750Historical High--Div YieldTTM9.01%Amplitude1.040Historical Low4.104Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Cumberland Pharmaceuticals Stock Forum
Breakthrough DMD Heart Disease Treatment Achieves 5.4% Function Boost While Controls Decline
$Cumberland Pharmaceuticals (CPIX.US)$
Cumberland Pharmaceuticals Inc -Vibativ Receives Marketing Approval in China
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Tuesday, 18th February at 7:30 am
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections
Approval in China paves the way for launch in world's second-largest market
NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" o...
No comment yet